Finasteride [For B.P.H.]
প্রস্তাবিত ডোজ হল প্রতিদিন একটি ৫ মিলিগ্রাম ট্যাবলেট। যদিও প্রাথমিক উন্নতি দেখা যেতে পারে, তবুও ঔষধে উপকার পাওয়া যাচ্ছে কিনা তা বুঝতে অন্তত ছয় মাসের জন্য চিকিত্সাটি চালিয়ে যেতে হতে পারে। এরপরে, পরবর্তী চিকিত্সা চালিয়ে যেতে হবে।
বিনাইন প্রোস্ট্যাটিক হাইপারপ্লাসিয়া (BPH)-এর চিকিৎসা ও নিয়ন্ত্রণের জন্য প্রোনর নির্দেশিত-বর্ধিত প্রস্টেটের রিগ্রেশন ঘটাতেপ্রস্রাব প্রবাহ বাড়াতেBPH এর সাথে যুক্ত উপসর্গ উন্নত করতে।
প্রোনর সাধারণত সহনীয়। ক্লিনিকাল স্টাডিতে, ১২ মাস ধরে প্রতিদিন ১ মিগ্রা ফাইনাস্টেরাইডের সাথে চিকিত্সারত ১% রোগীর মধ্যে সম্ভাব্য নিম্নলিখিত প্রতিকূল প্রতিক্রিয়াগুলি পাওয়া গেছে: পুরুষত্বহীনতা (৩.৭%), লিবিডো হ্রাস (৩.৩%), এবং বীর্যপাতের পরিমাণ হ্রাস (২.৮) %)।
আলো ও আর্দ্রতা থেকে দূরে, ৩০ ডিগ্রী সেঃ তাপমাত্রার নীচে রাখুন। শিশুদের নাগালের বাইরে রাখুন।
Finasteride, a competitive inhibitor of the 5α reductase enzyme which is used in the treatment of benign prostatic hyperplasia. It is selective for 5α reductase type 2 enzyme and has no affinity for androgen receptors. The development of the prostate gland and subsequent BPH is dependent upon conversion of testosterone to dihydrotestosterone (DHT) within the prostate. Finasteride belongs to a new class of specific inhibitors of 5α reductase, an intracellular enzyme, which metabolises testosterone into the more potent androgen, DHT. Finasteride has no affinity for the androgen receptor.
The recommended dosage is one 5 mg tablet daily. Although early improvement may be seen, treatment for at least six months may be necessary to assess whether a beneficial response has been achieved. Thereafter, treatment should be continued.
No clinically important drug interactions have been identified. Pronor does not appear to significantly affect the cytochrome P450 linked drug metabolising enzyme system. Compounds which have been tested in man include Propranolol, Digoxin, Glibenclamide, Warfarin, Theophylline, and antipyrine.
Hypersensitivity to any component of this medication. Finasteride use is also contraindicated in women and paediatric patient
Pronor is well tolerated. In clinical studies, the following adverse experiences have been reported as possibly drug related in 1% of patients treated for 12 months with 5 mg Pronor daily: impotence (3.7%), decreased libido (3.3%), and decreased volume of ejaculate (2.8%).
Finasteride is contraindicated in women who are or may become pregnant. Finasteride is not indicated for use in women. It is not known whether finasteride is excreted in human milk.Exposure to finasteride-risk to male fetus: Crushed or broken Finasteride Tablets should not be handled by women who are or may become pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus. Similarly, small amounts of finasteride have been recovered from the semen in subjects receiving Finasteride 5 mg/day. It is not known whether a male fetus may be adversely affected if his mother is exposed to the semen of a patient being treated with finasteride. Therefore, when the patients sexual partner is or may become pregnant, the patient should either avoid exposure of his partner to semen (e.g. by use of a condom) or discontinue Finasteride
General: Since the beneficial response to Pronor may not be manifested immediately, patients with large residual urine volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.Prostate cancer: Digital rectal examination, as well as, other evaluations for prostate cancer, should be performed on patients with BPH prior to initiating therapy with Pronor and periodically thereafter. Pronor causes a decrease in serum concentration of markers of prostatic cancer such as prostate specific antigen (PSA); therefore, reduction of serum levels of these markers in patients with BPH treated with Pronor does not rule out concomitant prostate cancer. No clinical benefit has yet been demonstrated in patients with prostate cancer treated with Pronor.
BPH/ Urinary retention/ Urinary incontinence
Store at cool and dry place (below 30°C). Protect from light and moisture. Keep all the medicines out of the reach of children.
Renal insufficiency: Dosage adjustments are not necessary in patients with renal insufficiency since pharmacokinetic studies did not indicate any change in the disposition of Pronor.Hepatic insufficiency: There are no data available in patients with hepatic insufficiency.Elderly: No dosage adjustment is required in elderly patients.
{'Indications': 'Pronor is indicated for the treatment and control of benign prostatic hyperplasia (BPH)-To cause regression of the enlarged prostateTo improve urinary flowTo improve the symptoms associated with BPH.'}